News | April 08, 2021
Zydus Cadila announces USFDA approval for Ibrutinib capsules
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection.
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The partnership is a significant step in delivering advanced cancer therapies to patients.
This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
Subscribe To Our Newsletter & Stay Updated
